现代膀胱癌症管理中的三联疗法 - Suppr

Suppr

超能文献

Trimodality therapy in the modern era for management of bladder cancer.

作者信息

Wang Shang-Jui

机构信息

Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

出版信息

Transl Cancer Res. 2024 Aug 31;13(8):3935-3939. doi: 10.21037/tcr-24-262. Epub 2024 Aug 20.

DOI:10.21037/tcr-24-262

PMID:39262470

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11385536/

Abstract

摘要

相似文献

Trimodality therapy in the modern era for management of bladder cancer.

Transl Cancer Res. 2024 Aug 31;13(8):3935-3939. doi: 10.21037/tcr-24-262. Epub 2024 Aug 20.

Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.

Eur Urol. 2019 Jul;76(1):59-68. doi: 10.1016/j.eururo.2019.01.011. Epub 2019 Feb 1.

Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions.

Curr Oncol Rep. 2020 Feb 1;22(2):14. doi: 10.1007/s11912-020-0880-5.

Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.

Crit Rev Oncol Hematol. 2015 Sep;95(3):387-96. doi: 10.1016/j.critrevonc.2015.04.006. Epub 2015 Apr 17.

Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.

Clin Transl Oncol. 2024 Feb;26(2):446-455. doi: 10.1007/s12094-023-03264-9. Epub 2023 Jun 30.

Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.

Eur J Med Res. 2023 Oct 11;28(1):422. doi: 10.1186/s40001-023-01408-9.

Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis.

J Oncol. 2022 May 14;2022:7306198. doi: 10.1155/2022/7306198. eCollection 2022.

Trimodality bladder preservation therapy for muscle-invasive bladder cancer.

J Natl Compr Canc Netw. 2013 Aug;11(8):952-60. doi: 10.6004/jnccn.2013.0116.

Trimodality therapy for bladder preservation in the elderly population with invasive bladder cancer.

Front Oncol. 2014 Aug 5;4:206. doi: 10.3389/fonc.2014.00206. eCollection 2014.

Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy.

JAMA Netw Open. 2022 Nov 1;5(11):e2242378. doi: 10.1001/jamanetworkopen.2022.42378.

本文引用的文献

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024).

J Urol. 2024 Jul;212(1):3-10. doi: 10.1097/JU.0000000000003981. Epub 2024 Apr 25.

Quality of life after definitive treatment for bladder cancer: A systematic review and meta-analysis.

Radiother Oncol. 2024 Jan;190:110038. doi: 10.1016/j.radonc.2023.110038. Epub 2023 Nov 30.

Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study.

Int J Radiat Oncol Biol Phys. 2024 Jan 1;118(1):41-49. doi: 10.1016/j.ijrobp.2023.07.027. Epub 2023 Jul 28.

Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer.

J Clin Oncol. 2023 Sep 20;41(27):4406-4415. doi: 10.1200/JCO.23.00725. Epub 2023 Jul 21.

Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.

Lancet Oncol. 2023 Jun;24(6):669-681. doi: 10.1016/S1470-2045(23)00170-5. Epub 2023 May 12.

Bladder Preservation for Muscle-Invasive Bladder Cancer With Variant Histology.

Semin Radiat Oncol. 2023 Jan;33(1):62-69. doi: 10.1016/j.semradonc.2022.10.008.

Current best practice for bladder cancer: a narrative review of diagnostics and treatments.

Lancet. 2022 Nov 12;400(10364):1712-1721. doi: 10.1016/S0140-6736(22)01188-6. Epub 2022 Sep 26.

Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.

Eur Urol. 2022 Sep;82(3):273-279. doi: 10.1016/j.eururo.2022.04.017. Epub 2022 May 14.

Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399).

Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1407-1415. doi: 10.1016/j.ijrobp.2021.03.001. Epub 2021 Mar 6.

Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials.

Lancet Oncol. 2021 Feb;22(2):246-255. doi: 10.1016/S1470-2045(20)30607-0.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验